SAN DIEGO, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( www.apricusbio.com) today announced a podium presentation titled, "Updated analyses of a randomized, double-blind, Phase 3 study of Femprox®, an alprostadil cream with a novel transdermal delivery technology (NexACT®) for the treatment of female sexual arousal disorder (FSAD)," will take place on Monday, August 27, 2012, at 4:30 p.m. CT, as part of the 2012 World Meeting on Sexual Medicine, which is being held August 26-30, 2012 in Chicago.
Apricus Biosciences Announces Podium Presentation Of Femprox(R) Phase III Clinical Data At 2012 World Meeting On Sexual Medicine
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.